OTC Medicines

Browse OTC Medicines Content

(WASHINGTON, D.C.) – The Consumer Healthcare Products Association (CHPA) released the following statement today following West Virginia Governor Jim Justice signing Senate Bill (SB) 688 into law. This legislation lifts the annual purchasing limits for common over-the-counter cold and allergy

Mar 6, 2024

“Consumers can be confident that over-the-counter (OTC) acne products containing benzoyl peroxide (BPO) are stable and safe under the specified storage conditions on their labels.

Mar 6, 2024

Washington, D.C. – The annual Monitoring the Future survey (MTF), conducted by researchers at the University of Michigan and funded by the National Institute on Drug Abuse (NIDA), shows that the percentage of adolescents reporting any substance use in 2023 continues to “hold steady” and remains below pre-pandemic levels, including abuse of over-the-counter (OTC) cough & cold medicines.

Dec 15, 2023

CHPA looks forward to working closely with FDA and other key stakeholders throughout the OMUFA reauthorization process as we work together to ensure the continued success of FDA’s OTC monograph program.

Oct 27, 2023

Timeline for FDA consideration of changes to the general recognition status of an OTC monograph ingredient under the standard procedure

Oct 20, 2023

(Washington, D.C.) – Consumer Healthcare Products Association (CHPA) Senior Vice President of Regulatory and Scientific Affairs Lisa Parks released the following statement today regarding the U.S. Food and Drug Administration’s

Sep 28, 2023

CHPA released a statement after submitting a Citizen Petition to the U.S. Federal Trade Commission (FTC) urging it to withdraw the Notice of Penalty Offenses Concerning Substantiation of Product Claims.

Sep 15, 2023

CHPA expresses disappointment in the recent NDAC recommendation and encourages FDA to consider the total weight of evidence before making any regulatory changes.

Sep 12, 2023

Filter Results